Peter Paul Yu, MD, FACP, FASCO, is a medical oncologist and haematologist and Director of Cancer Research at Palo Alto Medical Foundation, where he worked since 1989. In addition to his role as the 2014-2015 President of ASCO, Dr. Yu also serves on the Scientific Program, Nominating, Government Relations, and Special Awards Selection Committees. Since joining ASCO in 1986, Dr. Yu has served on the Quality of Care Committee, Strategic Planning Committee, Integrated Media and Technology Committee, Board of Directors, and Cancer Research Committee, among others. He has served as Chair of the Health Information Technology Workgroup, Clinical Practice Committee, and Best of ASCO Planning Committee, and as President of the Association of Northern California Oncologists (ANCO; an ASCO State/Regional Affiliate society). He was Co-Chair of the ASCO-NCI Clinical Oncology Requirements for the EHR Committee (2008). He is currently a columnist on ASCOconnection.org. In addition to his ASCO involvement, Dr. Yu is a member of the Cancer and Leukemia Group B as well as the Gynecologic Oncology Group. He is a Co-Chair of the Commission for the Certification of Health Information Technology Workgroups on Research and Oncology. Dr. Yu received his medical degree from Brown University, and performed his internship and residency in Internal Medicine at St. Luke’s-Roosevelt Hospital and a fellowship in neoplastic diseases at Mount Sinai Hospital. He was a Research Fellow and Associate at Memorial Sloan Kettering Cancer Center.

Nazneen Rahman is Professor of Human Genetics and Head of Division of Genetics & Epidemiology at The Institute of Cancer Research. She is also a genetics physician and Head of Cancer Genetics at The Royal Marsden. Her research work is directed towards identification and clinical characterisation of human disease genes, with her primary areas of research being breast, ovarian & childhood cancer susceptibility. She is currently leading a translational research programme which aims to implement testing for cancer predisposition genes into mainstream oncology services.

Born and raised in Scotland, Euan Angus Ashley graduated with 1st class Honors in Physiology and Medicine from the University of Glasgow. He completed medical residency and a PhD in molecular cardiology at the University of Oxford before moving to Stanford University where he trained in cardiology and advanced heart failure joining the faculty in 2006. His group is focused on the application of genomics to medicine. In 2010, he led the team that carried out the first clinical interpretation of a human genome. The paper published in the Lancet was the focus of over 300 news stories, became one of the most cited articles in clinical medicine that year, and is currently featured in the Genome Exhibition at the Smithsonian in DC. The team extended the approach in 2011 to a family of four and now routinely apply genome sequencing to the diagnosis of patients at Stanford hospital where Dr Ashley directs the Clinical Genome Service and the Center for Inherited Cardiovascular Disease. Dr Ashley is a recipient of the National Innovation Award from the American Heart Association (AHA) and a National Institutes of Health (NIH) Director’s New Innovator Award. He is a Principal Investigator of the Myocardial Applied Genomics Network (MAGnet), a member of the leadership group of the AHA Council on Functional Genomics, and a member of the Institute of Medicine (IOM) of the National Academy of Sciences Roundtable on Translating Genomic-Based Research for Health. He is a peer reviewer for the NIH and the AHA as well as journals including Nature, the New England Journal of Medicine, the Lancet and the Journal of Clinical Investigation,. He is co-founder of, and advisor to, Personalis, Inc, a Menlo Park based genetic diagnostics company.

This recording was taken at PMWC UK 2015 in Oxford. Jonathan Sheldon, Ph.D., is Global Vice President Healthcare responsible for Oracle Health Sciences healthcare analytics platform and solutions including in the areas of translational medicine, population health and convergence with Life Sciences. Previously, Dr. Sheldon was Chief Scientific Officer at InforSense, where he was responsible for the company’s strategic direction in the health sciences market, as well as leading the consulting group. Prior to InforSense, he was Chief Technology Officer for Confirmant Ltd, where he was responsible for developing the company’s proteomics products and services. He also established the first bioinformatics group and was Head of Bioinformatics for five years at Roche Welwyn, UK. Dr. Sheldon holds a Ph.D. in Molecular Biology/Biochemistry from the University of Cambridge.